ClinicalLiverDisease

Clinical Liver Disease (CLD) is an official digital learning resource of The American Association for the Study of Liver Diseases.

[AASLD @AASLDtweets]

Discover the latest insights in liver disease management in the FINAL issue of Clinical Liver Disease! @CLD_Learning https://t.co/pAfiWXtNWQ #LiverTwitter

[ClinicalLiverDisease @CLD_Learning]

Check out History of Hepatology collection on landmark events of our field!

Full collection- https://t.co/SWFwY2vGyN

Liver biopsy - https://t.co/XLtwYCeNYr

Liver transplant -
https://t.co/MbKCfXPMNR

Liver surgery -
https://t.co/5lEoWlrtFD

[ClinicalLiverDisease @CLD_Learning]

*New CLD series*
@BrettEFortune & Shari Royal expertly curated series on improving Quality of Care in Cirrhosis. An increasingly important topic.

Full series: https://t.co/BXT9THJkpN

Sample content:
https://t.co/jkABUvEJQt

https://t.co/C5Nvj29WCj

[ClinicalLiverDisease @CLD_Learning]

The evidence for fecal microbiota transplantation efficacy in liver disease continues to emerge

Read a comprehensive overview of the current state of play here:

https://t.co/vmmiJQfS9O

[ClinicalLiverDisease @CLD_Learning]

Addictive disorders are increasingly impacting liver disease outcomes

J Mellinger @lykhaque edit this crucial CLD series on addiction and liver disease. A must read!

Full series: https://t.co/mxIPw3bI9m

Sample content:
https://t.co/A5GUgNiJjA

https://t.co/A5GUgNiJjA

[ClinicalLiverDisease @CLD_Learning]

Opportunities for harnessing digital technologies to improve outcomes in cirrhosis. A great overview by the field leaders @jlouissaint89 @TiffanyWuMD

https://t.co/N6A3dhMhMQ

[Jeremy Louissaint @jlouissaint89]

⌚️Emerging #Digital Technologies to Help Patients with Cirrhosis📱 ‼️

✅out this review in @AASLDtweets @CLD_Learning where @TiffanyWuMD and I discuss how digital tools are reshaping #liver care!

#LiverTwitter
https://t.co/KLU06hGkBP

[ClinicalLiverDisease @CLD_Learning]

*NEW SERIES* edited by @serperm @yucaspice
Functional status is critical in determining outcomes in cirrhosis.

Nutrition: https://t.co/jx2n4uckpK

Untangling sarcopenia, frailty, and fitness: https://t.co/4nn1Znjmby

Series link (when all published) https://t.co/QSOdgFjjZu

[ClinicalLiverDisease @CLD_Learning]

Check out new articles added to our HCC series from debate on immunotherapy in LT, expansion of surgical candidates, biomarkers and updates on LT policy.

https://t.co/90ex2SOCTq
https://t.co/OgflVG2cbC
https://t.co/J3BYtbY7PZ
https://t.co/zTHTESHzxW
https://t.co/pPo9sTsRsY

[ClinicalLiverDisease @CLD_Learning]

A succinct review on management of hepatitis B reactivation. Risks and decision for prophylaxis are based on serologic status of patients and type of immunosuppressive therapy.
Helpful figure to guide decision making.

https://t.co/XEXw5w7N44

[ClinicalLiverDisease @CLD_Learning]

The role of immunotherapy in the evolving landscape of HCC treatment in the context of liver transplant.
Promising use needs to be balanced with allograft rejection
Expert opinion suggest a minimal of 12-week washout, more data needed

https://t.co/OXYIORXQy9

[ClinicalLiverDisease @CLD_Learning]

2 more from our Hep B elimination series https://t.co/BYv18srKDD

-Elimination: https://t.co/xoBlzPYbE5

-Functional cure (Anna Lok):
3%–5% after 10 yrs of nucleos(t)ide analogs; 8%–14% after 3–5 years of 48-wks of peg interferon. Trials also discussed
https://t.co/5rfxdX05OW

[ClinicalLiverDisease @CLD_Learning]

The most in-depth and interesting article on the evolution of the Cardio-Hepatology field, a truly unique relationship:

https://t.co/IMvLpX9ylI

See the entire series of History of Hepatology collection here:

https://t.co/KgiGEPzGhx

[ClinicalLiverDisease @CLD_Learning]

Check out two recently published articles on the advances in Hepaititis B and Hepatitis D treatments!

https://t.co/CaKWknSBPa

https://t.co/mSAOxHgmPT

[ClinicalLiverDisease @CLD_Learning]

@agud__MD @AlexanderPodboy explore the ever expanding field of endo-bariatric therapies in treating MASLD

Endo Balloon & Sleeve Gastroplasty nuances and efficacy expertly discussed

https://t.co/iHztyvdPw3

[ClinicalLiverDisease @CLD_Learning]

@RobertFontanaMD & colleagues @MichiganLiver guide us through the challenging (& common) scenario of how to establish a diagnosis of DILI in patients on chemotherapy in a stepwise fashion

A case of PKI-associated cholestatic granulomatous hepatitis:

https://t.co/qVKmJ4Kw44

[ClinicalLiverDisease @CLD_Learning]

Two interesting articles on infantile cholestasis

1. Renal lesion associations: https://t.co/oi4AuusjAP

2. Biliary atresia case:
https://t.co/GfqmY4fibh

@anouti_ahmad @BAREInc_org

[ClinicalLiverDisease @CLD_Learning]

@RobertFontanaMD & colleagues @MichiganLiver guide us through the challenging (& common) scenario of how to establish a diagnosis of DILI in patients on chemotherapy in a stepwise fashion

A case of PKI-associated cholestatic granulomatous hepatitis:

https://t.co/qVKmJ4Kw44

[ClinicalLiverDisease @CLD_Learning]

CLD series is curated by our Guest Editors to bring articles together to capture intent of the series. https://t.co/3mlq57eGVk

Check out the new content added to the "Pregnancy and Liver Disease" series.
https://t.co/rg9s7D5Gns

https://t.co/8rPIbLSwdT

https://t.co/BRxIwvWY4K

[ClinicalLiverDisease @CLD_Learning]

@agud__MD @AlexanderPodboy explore the ever expanding field of endo-bariatric therapies in treating MASLD

Endo Balloon & Sleeve Gastroplasty nuances and efficacy expertly discussed

https://t.co/iHztyvdPw3

[ClinicalLiverDisease @CLD_Learning]

Metabolic Disorders play an important role in modifying hepatitis B outcomes

From our upcoming "Current Challenges in the Management of Chronic Hepatitis B Infection" series collection:

https://t.co/6333RzgmT5